Kathy Cooley
Physician Assistant · Eastpointe, MINPI 1710176946
Payments from drug & device makers
Across 311 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Ironwood Pharmaceuticals, Inc$607
- Otsuka America Pharmaceutical, Inc.$527
- AstraZeneca$417
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
- GSK$324
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,655100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,848 |
| Ironwood Pharmaceuticals, Inc | 34 | $607 |
| Otsuka America Pharmaceutical, Inc. | 24 | $527 |
| AstraZeneca | 16 | $417 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $357 |
| GSK | 24 | $324 |
| Indivior Inc. | 6 | $203 |
| USWM, LLC | 9 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Exact Sciences | 5 | $97 |
| Novo Nordisk | 6 | $95 |
| Braeburn Inc. | 1 | $88 |
| Pfizer | 5 | $82 |
| Lundbeck LLC | 3 | $75 |
| Johnson & Johnson | 4 | $61 |
| Alkermes, Inc. | 2 | $55 |
| Gilead | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $46 |
| Amgen | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Orexo US, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Virtus Pharmaceuticals LLC | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$5,655 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $58,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $57,950 |
| LinzessLinaclotide | 88 | $47,214 |
| TrulicityDulaglutide | 35 | $33,610 |
| EliquisApixaban | 36 | $27,330 |
| FarxigaDapagliflozin Propanediol | 23 | $21,849 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $16,892 |
| AptiomEslicarbazepine Acetate | 14 | $16,728 |
| RybelsusSemaglutide | 19 | $16,354 |
| Varenicline Tartrate | 42 | $12,615 |
| JanuviaSitagliptin Phosphate | 17 | $9,479 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $9,376 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,252 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 512 | $8,092 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $7,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $95 | $74,43273 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $324 | $67,975117 claims |
| AbbVieLinzess, Combigan, Lumigan | $1,848 | $54,420120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $417 | $44,36877 claims |
| Lilly USA, LLCTrulicity | $36 | $33,61035 claims |
| PfizerEliquis | $82 | $27,33036 claims |
| Indivior Inc.Suboxone | $203 | $9,37622 claims |
| Boehringer IngelheimCombivent Respimat | $38 | $9,25219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Eastpointe
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.